A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2036

Study Completion Date

December 31, 2036

Conditions

Multiple Myeloma

Interventions

DRUG

Linvoseltamab

Administered per the protocol

DRUG

Daratumumab

Administered per the protocol

DRUG

Lenalidomide

Administered per the protocol

DRUG

Dexamethasone

Administered per the protocol

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

European Myeloma Network B.V.

NETWORK